Oculus Innovative Sciences, Inc. Share Price Nasdaq
Equities
US67575P2074
Pharmaceuticals
End-of-day quote
Other stock markets
|
||
- USD | - |
Sales 2024 * | 14.7M 1.23B | Sales 2025 * | 17.9M 1.49B | Capitalization | 3.9M 325M |
---|---|---|---|---|---|
Net income 2024 * | -5M -417M | Net income 2025 * | -3M -250M | EV / Sales 2024 * | 0.27 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.22 x |
P/E ratio 2024 * |
-0.28
x | P/E ratio 2025 * |
-0.56
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.44% |
Managers | Title | Age | Since |
---|---|---|---|
Amy Trombly
CEO | Chief Executive Officer | 57 | 27/19/27 |
John Poggetto
DFI | Director of Finance/CFO | 53 | 01/02/01 |
Jerome Dvonch
DFI | Director of Finance/CFO | 56 | 08/20/08 |
Members of the board | Title | Age | Since |
---|---|---|---|
Amy Trombly
CEO | Chief Executive Officer | 57 | 27/19/27 |
Jay Birnbaum
BRD | Director/Board Member | 79 | 20/07/20 |
Director/Board Member | 64 | 19/18/19 |
1st Jan change | Capi. | |
---|---|---|
+32.36% | 694B | |
+30.11% | 593B | |
-1.60% | 371B | |
+20.07% | 331B | |
+6.04% | 290B | |
+14.43% | 239B | |
+10.13% | 209B | |
-3.19% | 209B | |
+9.27% | 169B |